It catches my eye, yet this lacks the structure of a controlled trial or item. The aim is obvious, with straightforward metrics that could be included to observe during subsequent phased testing.
I appreciate them pursuing projects of this sort and noting the constraints promptly. It would be good if they extended this approach to places like these discussions and additional compounds of that type. The authors warn that the outcomes don't establish direct links. One can't conclude these medications produce the reported effects, according to the lead researcher who is a grad student. Still, close to four percent of the platform participants mentioned changes in their periods, and that rate could rise when focusing solely on women. It looks like an indication that deserves more attention.